Clinical Trial Update: Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients [Phase 2]

View source ↗

Summary

Phase 2 study of NTx-265 (hCG and epoetin alfa) in acute ischemic stroke was terminated. Results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• NTx-265

Snippet

Sponsor: Stem Cell Therapeutics Corp. | Conditions: Stroke | Phase 2 | Status: TERMINATED | Results posted: 2011-11-09